Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Koizumi, Mitsuru ^a,b   Yoshimoto, Masataka ^b,c   Kasumi, Fujio ^b,d   Iwase, Takuji ^b   Ogata, Etsuro ^b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c International University of Health and Welfare Mita Hospital   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; TUMOR MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; VISUAL ANALOG SCALE; ADULT; AGED; BONE TUMOR; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; PAIN; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PAIN; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77955489897     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-423     Document Type: Article

References (25)

1. Galasko CSB. The anatomy and pathways of skeletal metastases. Bone metastases 1981, 49-63. Boston: GK Hall, Weiss L, Gilbert AH.
2. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield, Davidson NE. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006, 24:5091-5097. 10.1200/JCO.2006.08.8575, 17033037.
3. Rojas MP, Telaro E, Moschetti I, Coe L, Fossati R, Libereti A, Rosselli MDT. Follow-up strategies for women treated for early breast cancer. Cochrane Database of Systemic Review 2009, 2.
4. The GIVCO investigators Impact of follow-up testing on survival and health-related quality of life in breast cancer. JAMA 1994, 27:1587-1592. The GIVCO investigators.
5. Rosselli der Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Counsil Project on Breast Cancer follow-up. JAMA 1994, 27:1593-1597.
6. Hamilton A, Hortobagyi G. Chemotherapy: what progress in last 5 year?. J Clin Oncol 2005, 23:1760-1775. 10.1200/JCO.2005.10.034, 15755984.
7. Thurlimann B, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A. A comparison of letrozol and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. 10.1056/NEJMoa052258, 16382061.
8. Romond EH, Perez EA, Bryant JB, Suman VJ, Geyer CE, Davidson NE, Tan-chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Marmounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
9. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med 1996, 335:1785-1791. 10.1056/NEJM199612123352401, 8965890.
10. Kanis JA, Powles T, Paterson AHG, MaCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19:663-667. 10.1016/S8756-3282(96)00285-2, 8968035.
11. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363. 10.1056/NEJM199808063390601, 9691101.
12. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastasis from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321. 10.1200/JCO.2005.05.116, 15738536.
13. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG. American society clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000, 18:1378-1391.
14. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003, 14:1234-1240. 10.1093/annonc/mdg348, 12881385.
15. Pedrazzini A, Gelber R, Isley M, Castiglione M, Goldhirsch A. First repeated bone scan in observation of patients with operable breast cancer. J Clin Oncol 1986, 4:389-394.
16. Sobin LH, Wittekind C, . editors UICC, TNM classification of malignant tumours. 2002, New York: Wiley-Liss, sixth, editors.
17. The Japanese Breast Cancer Society General Rules for Clinical and Pathological Recording of Breast Cancer. 2000, Tokyo: Kimbara, 14, The Japanese Breast Cancer Society.
18. Sakamoto G. Infiltrating carcinoma: major histological types. Diagnostic histopathology of the breast 1987, 193-235. New York: Churchill Livingstone, Page DL, Anderson TJ.
19. Font D, Schneck SO, Frankel A, Robinson E. Bone metastases and bone pain in breast cancer. Are they closely associated?. JAMA 1979, 242:1747-1748. 10.1001/jama.242.16.1747, 480600.
20. Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med 2002, 16:161-168. 10.1007/BF02996296, 12126040.
21. Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003, 23:4095-4100.
22. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB. The relative utility of eight collagenous and non-collagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiology, Biomarkers & Prevention 2006, 15:32-38.
23. Cook GS, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET differing metabolic activity in osteoblastic and osteolytic lesion. J Clin Oncol 1998, 10:3357-3359.
24. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T, Nishimura T. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005, 32:1253-1258. 10.1007/s00259-005-1842-8, 16133397.
25. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Trager H, Nussle K, Reske SN. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629.